Format

Send to

Choose Destination
Clin Pharmacol Ther. 2017 Feb;101(2):230-238. doi: 10.1002/cpt.568. Epub 2016 Dec 20.

Medical cannabis: Another piece in the mosaic of autoimmunity?

Author information

1
The Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
2
Faculty of Medicine, The Hebrew University of Jerusalem, Israel.
3
The Robert H. Smith Faculty of Agriculture, Food and Environment School of Nutritional Sciences, The Hebrew University of Jerusalem, Rehovot, Israel.
4
Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel.

Abstract

Legalization of cannabis' medicinal use is rapidly increasing worldwide, raising the need to evaluate medical implications of cannabis. Currently, evidence supports cannabis and its active ingredients as immune-modulating agents, affecting T-cells, B-cells, monocytes, and microglia cells, causing an overall reduction in pro-inflammatory cytokine expression and an increase in anti-inflammatory cytokines. Due to the supporting evidence of cannabinoids as an immune-modulating agent, research focusing on cannabinoids and autoimmunity has emerged. Several clinical trials in multiple sclerosis, inflammatory bowel disease, and fibromyalgia suggest cannabis' effectiveness as an immune-modulator. However, contradicting results and lack of large-scale clinical trials obscure these results. Although lacking clinical research, in vitro and in vivo experiments in rheumatoid arthritis, diabetes type 1, and systemic sclerosis demonstrate a correlation between disease activity and cannabinoids.

PMID:
27859024
DOI:
10.1002/cpt.568
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center